Acute Pancreatitis Incidence with Wegovy
Based on FDA drug label data, acute pancreatitis occurred in approximately 0.2% of Wegovy-treated patients in clinical trials, translating to 0.2 cases per 100 patient-years of exposure compared to less than 0.1 cases per 100 patient-years in placebo-treated patients 1.
Specific Incidence Data
The FDA-approved prescribing information for Wegovy provides the most authoritative data:
- Adult trials: 4 confirmed cases of acute pancreatitis in Wegovy-treated patients (0.2 cases per 100 patient-years) versus 1 case in placebo patients (<0.1 cases per 100 patient-years) 1
- Additional case: One more acute pancreatitis case was confirmed in another Wegovy clinical trial 1
- Pediatric trials (ages ≥12 years): No specific pancreatitis incidence reported in the pediatric obesity trial data provided 1
Context and Clinical Implications
Risk Assessment
The absolute risk remains low at approximately 1 in 500 patients based on the clinical trial data. This represents roughly a 2-fold increase compared to placebo, though the baseline rate is already very low 1.
Evidence Quality
Recent meta-analyses provide reassuring data that contradicts earlier concerns:
- A 2024 meta-analysis of 21 trials including 34,721 patients found no increased risk of acute pancreatitis with semaglutide overall (OR 0.7; 95% CI 0.5-1.2), including when stratified by dosing regimen 2
- A 2025 meta-analysis showed a slightly increased risk (RR: 1.44,95% CI 1.09-1.89), but this became non-significant when stratified by background medication use 3
Important Caveats
Diagnostic misclassification is a major confounder: Many suspected pancreatitis cases in GLP-1 RA users may actually represent severe gastrointestinal adverse effects (nausea, vomiting, abdominal pain) rather than true acute pancreatitis 4. The overlap in symptoms can lead to unnecessary workups and false attribution.
Patient selection matters: Case reports demonstrate that pancreatitis can occur even after prolonged use (2.5 years) and may be more concerning in patients with multimorbidity, chronic kidney disease, or other metabolic stressors 5.
History of pancreatitis: While the FDA label lists "history of pancreatitis" as a contraindication in some contexts 6, one guideline notes that pancreatitis is "a precaution but not a contraindication" for liraglutide 7, suggesting nuanced risk-benefit assessment is appropriate.
Clinical Monitoring
Watch for classic pancreatitis symptoms during treatment:
- Severe persistent abdominal pain radiating to the back
- Nausea and vomiting that differs from typical GLP-1 RA gastrointestinal effects
- Elevated lipase/amylase levels
Discontinue Wegovy immediately if acute pancreatitis is suspected or confirmed 1. Do not restart if pancreatitis is confirmed.